Tenpoint Therapeutics is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis Pharma, and LENZ Therapeutics, after getting FDA approval for its Yuvezzi product. Presbyopia is a condition that typically starts in middle age and involves difficulty in focusing on near objects. At one point, the market potential for Vuity was predicted to be in the region of $500 million a year. In clinical trials, the drug corrected vision for up to 10 hours, with good tolerability, according to Tenpoint. It has just completed a $235 million Series B financing and credit facility to fund the scaling of commercial operations in anticipation of the launch of Yuvezzi.